57 related articles for article (PubMed ID: 37954220)
21. Lymphoma complicating rheumatoid arthritis: results from a French case-control study.
Kedra J; Seror R; Dieudé P; Constantin A; Toussirot E; Kfoury E; Masson C; Cornec D; Dubost JJ; Marguerie L; Ottaviani S; Grados F; Belkhir R; Fain O; Goupille P; Sordet C; Fautrel B; Philippe P; Piperno M; Combe B; Lambotte O; Richez C; Sellam J; Sené T; Denis G; Lequerre T; Lazure T; Mariette X; Nocturne G
RMD Open; 2021 Sep; 7(3):. PubMed ID: 34470830
[TBL] [Abstract][Full Text] [Related]
22. Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice.
Huss V; Bower H; Wadström H; Frisell T; Askling J;
Rheumatology (Oxford); 2022 May; 61(5):1810-1818. PubMed ID: 34324640
[TBL] [Abstract][Full Text] [Related]
23. Female hormonal exposures and risk of rheumatoid arthritis in the French E3N-EPIC cohort study.
Salliot C; Nguyen Y; Gusto G; Gelot A; Gambaretti J; Mariette X; Boutron-Ruault MC; Seror R
Rheumatology (Oxford); 2021 Oct; 60(10):4790-4800. PubMed ID: 33547777
[TBL] [Abstract][Full Text] [Related]
24. Pancreatic manifestations in rheumatoid arthritis: a national population-based study.
Alkhayyat M; Abou Saleh M; Grewal MK; Abureesh M; Mansoor E; Simons-Linares CR; Abelson A; Chahal P
Rheumatology (Oxford); 2021 May; 60(5):2366-2374. PubMed ID: 33244600
[TBL] [Abstract][Full Text] [Related]
25. Lymphoma risks in patients with rheumatoid arthritis treated with biological drugs-a Swedish cohort study of risks by time, drug and lymphoma subtype.
Hellgren K; Di Giuseppe D; Smedby KE; Sundström C; Askling J; Baecklund E;
Rheumatology (Oxford); 2021 Feb; 60(2):809-819. PubMed ID: 32810256
[TBL] [Abstract][Full Text] [Related]
26. Risk of breast cancer before and after rheumatoid arthritis, and the impact of hormonal factors.
Wadström H; Pettersson A; Smedby KE; Askling J
Ann Rheum Dis; 2020 May; 79(5):581-586. PubMed ID: 32161056
[TBL] [Abstract][Full Text] [Related]
27. B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma.
Griss J; Bauer W; Wagner C; Simon M; Chen M; Grabmeier-Pfistershammer K; Maurer-Granofszky M; Roka F; Penz T; Bock C; Zhang G; Herlyn M; Glatz K; Läubli H; Mertz KD; Petzelbauer P; Wiesner T; Hartl M; Pickl WF; Somasundaram R; Steinberger P; Wagner SN
Nat Commun; 2019 Sep; 10(1):4186. PubMed ID: 31519915
[TBL] [Abstract][Full Text] [Related]
28. Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study.
Ozen G; Pedro S; Schumacher R; Simon TA; Michaud K
Arthritis Res Ther; 2019 Jun; 21(1):141. PubMed ID: 31174592
[TBL] [Abstract][Full Text] [Related]
29. [Descriptive epidemiology of cancer in metropolitan France: Incidence, survival and prevalence].
Cowppli-Bony A; Colonna M; Ligier K; Jooste V; Defossez G; Monnereau A; ;
Bull Cancer; 2019; 106(7-8):617-634. PubMed ID: 30833045
[TBL] [Abstract][Full Text] [Related]
30. Abatacept initiation in rheumatoid arthritis and the risk of cancer: a population-based comparative cohort study.
Montastruc F; Renoux C; Dell'Aniello S; Simon TA; Azoulay L; Hudson M; Suissa S
Rheumatology (Oxford); 2019 Apr; 58(4):683-691. PubMed ID: 30535094
[TBL] [Abstract][Full Text] [Related]
31. Pancreatic cancer and autoimmune diseases: An association sustained by computational and epidemiological case-control approaches.
Gomez-Rubio P; Piñero J; Molina-Montes E; Gutiérrez-Sacristán A; Marquez M; Rava M; Michalski CW; Farré A; Molero X; Löhr M; Perea J; Greenhalf W; O'Rorke M; Tardón A; Gress T; Barberá VM; Crnogorac-Jurcevic T; Muñoz-Bellvís L; Domínguez-Muñoz E; Balsells J; Costello E; Yu J; Iglesias M; Ilzarbe L; Kleeff J; Kong B; Mora J; Murray L; O'Driscoll D; Poves I; Lawlor RT; Ye W; Hidalgo M; Scarpa A; Sharp L; Carrato A; Real FX; Furlong LI; Malats N;
Int J Cancer; 2019 Apr; 144(7):1540-1549. PubMed ID: 30229903
[TBL] [Abstract][Full Text] [Related]
32. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
Wadström H; Frisell T; Askling J;
JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of algorithms to identify incident cancer cases by using French health administrative databases.
Ajrouche A; Estellat C; De Rycke Y; Tubach F
Pharmacoepidemiol Drug Saf; 2017 Aug; 26(8):935-944. PubMed ID: 28485129
[TBL] [Abstract][Full Text] [Related]
34. Cervical neoplasia in systemic lupus erythematosus: a nationwide study.
Wadström H; Arkema EV; Sjöwall C; Askling J; Simard JF
Rheumatology (Oxford); 2017 Apr; 56(4):613-619. PubMed ID: 28039412
[TBL] [Abstract][Full Text] [Related]
35. Prevalence and economic burden of cardiovascular diseases in France in 2013 according to the national health insurance scheme database.
Tuppin P; Rivière S; Rigault A; Tala S; Drouin J; Pestel L; Denis P; Gastaldi-Ménager C; Gissot C; Juillière Y; Fagot-Campagna A
Arch Cardiovasc Dis; 2016; 109(6-7):399-411. PubMed ID: 27079468
[TBL] [Abstract][Full Text] [Related]
36. Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden.
Raaschou P; Simard JF; Asker Hagelberg C; Askling J;
BMJ; 2016 Jan; 352():i262. PubMed ID: 26823527
[TBL] [Abstract][Full Text] [Related]
37. Risk of multiple myeloma in rheumatoid arthritis: a meta-analysis of case-control and cohort studies.
Shen K; Xu G; Wu Q; Zhou D; Li J
PLoS One; 2014; 9(3):e91461. PubMed ID: 24626254
[TBL] [Abstract][Full Text] [Related]
38. Lymphoma development in patients with autoimmune and inflammatory disorders--what are the driving forces?
Baecklund E; Smedby KE; Sutton LA; Askling J; Rosenquist R
Semin Cancer Biol; 2014 Feb; 24():61-70. PubMed ID: 24333759
[TBL] [Abstract][Full Text] [Related]
39. Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population.
Mercer LK; Davies R; Galloway JB; Low A; Lunt M; Dixon WG; Watson KD; Symmons DP; Hyrich KL;
Rheumatology (Oxford); 2013 Jan; 52(1):91-8. PubMed ID: 23238979
[TBL] [Abstract][Full Text] [Related]
40. Incidences of overall and site specific cancers in TNFα inhibitor treated patients with rheumatoid arthritis and other arthritides - a follow-up study from the DANBIO Registry.
Dreyer L; Mellemkjær L; Andersen AR; Bennett P; Poulsen UE; Juulsgaard Ellingsen T; Hansen TH; Jensen DV; Linde L; Lindegaard HM; Loft AG; Nordin H; Omerovic E; Rasmussen C; Schlemmer A; Tarp U; Hetland ML
Ann Rheum Dis; 2013 Jan; 72(1):79-82. PubMed ID: 22945500
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
